Optimal use of modern antibiotics: Emerging trends

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 264-274

  Polk, Ron ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFMENOXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG PREFERENCE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; OTITIS MEDIA; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TREATMENT INDICATION;

EID: 0032769566     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520196     Document Type: Article

References (79)

1. 1. Shlaes DM, Gerding DN, John JF, et al. Society for Health Care Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-99.
2. 2. Jarvis WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect Control Hosp Epidemiol 1996;17:490-5.
3. 3. Marr JJ, Moffet H, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 1988;157:869-76.
4. 4. John JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-85.
5. 5. McGowan JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478-83.
6. 6. Reese RE, Betts RF. Antibiotic use. In: Reese RE, Betts RF, eds. Handbook of antibiotics. 2nd ed. Boston: Little, Brown, 1993:1059-97.
7. 7. Thompson RL, Wright AJ. General principles of antibiotic therapy. Mayo Clin Proc 1998;73:995-1006.
8. 8. Levin BR, Anita R, Berliner E, et al. Resistance to antimicrobial chemotherapy: a prescription for research and action. Am J Med Sci 1998; 315:87-94.
9. 9. Bryan CS. The role of the infectious diseases physician in setting guidelines for antimicrobial use. Bull NY Acad Med 1987;63:627-37.
10. 10. Gross PA. Practice guidelines for infectious diseases: rationale for a work in progress. Clin Infect Dis 1998;26:1037-41.
11. 11. The choice of antibacterial drugs. Med Lett Drugs Ther 1998;40:33-42.
12. 12. Bartlett JG. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semin Respir Infect 1997;12:329-33.
13. 13. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26:811-38.
14. 14. Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998;11: 628-44.
15. 15. Bradley JS, Scheld WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis 1997;24(suppl 2):S213-21.
16. 16. 1998 drug topics red book. Montvale, NJ: Medical Economics Company, 1998.
17. 17. Joshi N, Miller D. Doxycycline revisited. Arch Intern Med 1997;157: 1421-8.
18. 18. Cunha BA. Community-acquired pneumonia. Cost-effective antimicrobial therapy. Postgrad Med 1996;99:109-10, 113-4, 117-9.
19. 19. Felmingham D, Gruneberg RN. Comparative in-vitro activity of 16 antimicrobials against 6943 community-acquired LRTI isolates: The Alexander Project 1997 [abstract no. 198]. In: Program and abstracts of the 36th annual meeting of the Infectious Diseases Society of America (Denver). Alexandria, VA: Infectious Diseases Society of America, 1998:113.
20. 20. McNally C, Plouffe JF, Hackman B, et al. Antimicrobial resistance and serotype distribution of bacteremic isolates of streptococcus pneumoniae [abstract no. E-78]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:191.
21. 21. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones R. Prevalence of antimicrobial resistance among respiratory isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27:64-70.
22. 22. Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-93.
23. 23. Luitse S, Franssen RM, Hogenboom RM, Hengeveld WL. Treatment of acute respiratory tract infections with doxycyclinc in general practice. Chemotherapy 1975;21(suppl 1):136-42.
24. 24. Titscher R. Doxycycline in the treatment of upper and lower respiratory tract infections. A field trial. Chemotherapy 1975;21(suppl 1):109-15.
25. 25. Meier J. Doxycycline in respiratory tract infections. A review of a multicentre trial. Chemotherapy 1975;21(suppl 1):130-5.
26. 26. Roy DC, Marwah SM, Rout BC, Mania R. Doxycycline in the treatment of lower respiratory tract infections. J Postgrad Med 1980;26:225-30.
27. 27. Casado MJ. Doxycycline in respiratory tract infections. Report of a retrospective study in Spain during the winter 1972-1973. Chemotherapy 1975;21(suppl 1):76-90.
28. 28. File T, Segretti J, Dunbar L, et al. A multicenter randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
29. 29. Harazim H, Wimmer J, Mittermayer HP. An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. Drugs 1987;34(suppl 1):71-3.
30. 30. Norrby RS. Atypical pneumonia in the Nordic countries: etiology and clinical results of a trial comparing fleroxacin and doxycycline. J Antimicrob Chemother 1997;39:499-508.
31. 31. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycyclinc is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999;159:266-70.
32. 32. Baquero F, Negri MC. Strategies to minimize the development of antibiotic resistance. J Chemother 1997;9(suppl 3):29-37.
33. 33. Boyce JM. Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures. Infect Dis Clin North Am 1997;11:367-84.
34. 34. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Clin Infect Dis 1999;29:245-52.
35. 35. Plouffe JF, McNally C, File TM Jr. Value of noninvasive studies in community-acquired pneumonia. Infect Dis Clin North Am 1998;12: 689-99.
36. 36. Leggiadro RJ. The clinical impact of resistance in the management of pneumococcal disease. Infect Dis Clin North Am 1997;11:867-74.
37. 37. Tremolieres F, de Kock F, Pluck N, Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998;17:447-53.
38. 38. Carbon C, International Study Group. Comparative study of levofloxacin (LVFX) and co-amoxiclav (Co-AC) in the treatment of community-acquired pneumoniae in adults [abstract no. LM-73]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:378.
39. 39. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998;42:2375-9.
40. 40. Niederman M, Traub S, Ellison WT, Hopkins DW, Trovan Pneumonia Study Group. A double-blind, randomized, multicenter, global study in hospitalized community acquired pneumonia (CAP) comparing trovafloxacin with ceftriaxone + erythromycin [abstract no. LM-72]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:377.
41. 41. Mandell L, Hopkins DW, Hopkins S. Efficacy of trovafloxacin in patients with community acquired pneumoniae due to penicillin susceptible and resistant S. pneumoniae [abstract no. LM-71]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:377.
42. 42. Young LS. Editorial response: a new fluoroquinolone for community acquired pneumonia. Clin Infect Dis 1998;26:1322-3.
43. 43. File TM Jr, Tan JS, Plouffe JF. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 1998;12: 569-92.
44. 44. MacGowan AP, Bowker KE. Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. J Infect 1998;37(suppl 1):30-6.
45. 45. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-7.
46. 46. MacGowan AP, Bowker KE, Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9(suppl 3):38-44.
47. 47. Estes L. Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin Proc 1998;73:1114-22.
48. 48. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
49. 49. Israel D, Gillum G, Turik M, et al. Pharmacokinetics and pharmacodynamics of multiple-dose ciprofloxacin and ofloxacin in normal volunteers. Antimicrob Agents Chemother 1993;37:2193-9.
50. 50. Schentag JJ. Antibiotic dosing - does one size fit all? JAMA 1998;279: 159-60.
51. 51. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279: 125-9.
52. 52. Prescribing information: Raxar. Glaxo Wellcome, 1997.
53. 53. Prescribing information: Trovan. Pfizer, 1997.
54. 54. Andes D, Van Ogtrop ML, Craig WA. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model [abstract no. A-9]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:3.
55. 55. Hyatt JM, Ballow CH, Forrest A, Turnak MR, Stalker DJ, Schentag JJ. Safety and efficacy of linezolid (PNU-100766) in eradication of nasal Staphylococcus aureus [abstract no. A-4]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:1.
56. 56. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
57. 57. Low D, Scheld WM. Strategies for stemming the tide of antimicrobial resistance. JAMA 1998;279:394-5.
58. 58. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997;41:363-73.
59. 59. Craig WA. Qualitative susceptibility tests versus quantitative MIC tests. Diagn Microbiol Infect Dis 1993;16:231-6.
60. 60. Dowell SF, Marcy SM, Phillips WR, et al. Otitis media - principles of judicious use of antimicrobial agents. Pediatrics 1998;101(suppl): 165-71.
61. 61. Siegel RE, Greene JG, Cashin R, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71.
62. 62. Cassiere HA, Fein AM. Duration and route of antibiotic therapy in community-acquired pneumonia: switch and step-down therapy. Semin Respir Infect 1998;13:36-42.
63. 63. Martin MV, Hardy P, Hill JB, Longman LP. Acute dentoalveolar infections: an investigation of the duration of antibiotic therapy. Br Dent J 1997;183:135-7.
64. 64. Wittmann DH. Duration of antibiotic treatment in surgical infections of the abdomen. Pharmacokinetic basis for short courses of antimicrobial therapy. Eur J Surg Suppl 1996;576:19-23.
65. 65. Ehl S, Pohlandt F, Hogel J, Bartmann P, Gering B. C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics 1997;99:216-21.
66. 66. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
67. 67. Kozyrskyj AL, Hildes-Ripstein GE, Longstaff SEA, et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA 1998;279:1736-42.
68. 68. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis, and tonsillopharyngitis, Pediatr Infect Dis J 1997;314:1526-9.
69. 69. Cantekin EI. The changing paradigm for acute otits media. JAMA 1998; 280:1902-3.
70. 70. Del Mar C, Glasziou P, Hayem M. Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis. Br Med J 1997;314:1526-9.
71. 71. Vanhove GF, Blaschke TF, Merigan TC, Winters MA, Schapiro JM. Patient compliance and drug failure in protease inhibitor monotherapy [letter]. JAMA 1996;276:1955-6.
72. 72. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:365-70.
73. 73. Williams RJ, Heymann DL. Containment of antibiotic resistance. Science 1998;279:1153-4.
74. 74. Burke JP. Antibiotic resistance - squeezing the balloon? JAMA 1998;280: 1270-1.
75. 75. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effects of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-6.
76. 76. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;14:1233-7.
77. 77. Frank MO, Batteiger BE, Sorensen SJ, et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care 1997;5:180-8.
78. 78. White AC, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-9.
79. 79. Centers for Disease Control and Prevention. Program announcement 98039: programs to prevent the emergence and spread of antimicrobial resistance. Fed Regist 1998;63:25483-8.